BCL2L14

Across TCGA pan-cancer cohorts, BCL2L14 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated BCL2L14 data layer compared with 26 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BCL2L14 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated BCL2L14 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where BCL2L14 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.698	0.408	<.001	40	view →
LUAD	DFS	Tertile	III,IV	0.879	0.221	.003	13	view →
LSCC	DFS	Median	All	1.000	0.518	.030	4	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

BCL2L14–PDAC (OS)

Open the PDAC breakdown →